Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
IOVA Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Iovance Biotherapeutics, Inc.NASDAQ: IOVA
Accounts Payables · Q3 FY2026 · quarter ended Sep 2026
Accounts payables declines year over year
Q3 FY2026 accounts payables of $2.6M (cash outflow) fell 40.8% year over year, ahead of the -50.2% change in trailing-twelve-month accounts payables. Sequentially, it fell 78.0% from the prior quarter.
Context
- Accounts payables amounted to 2.5% of revenue in FY2025, down 2.3 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -40.8% holds above the trailing-twelve-month pace of -50.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (6.66M) USD
- Year-over-year change
- +15.0%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.66M) | +15.0% |
| FY2024 | 2024-12-31 | (7.84M) | -262.4% |
| FY2023 | 2023-12-31 | 4.83M | -17.9% |
| FY2022 | 2022-12-31 | 5.88M | -15.7% |
| FY2021 | 2021-12-31 | 6.98M | — |
Accounts Payables vs competitors
How IOVA compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -50.2% is the 2nd highest of 10, against a peer median of -119.2%.
- Accounts payables amounts to 1.0% of revenue for IOVA, versus a peer median of 3.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €834.85M EUR | -430.3% | — | 31.6% | |
| LTM Jun 2026 | $37.17M USD | — | +12.3% | 0.9% | |
| LTM Sep 2026 | $26.31M USD | -138.8% | -15.0% | 1.9% | |
| LTM Sep 2026 | $6.44M USD | +246.9% | — | 3.5% | |
| LTM Mar 2026 | $5.77M USD | -408.6% | — | 91.4% | |
| LTM Sep 2026 | $3.74M USD | -50.2% | — | 1.0% | |
| LTM Sep 2026 | $1.13M USD | -147.6% | +138.3% | — | |
| LTM Dec 2025 | $654K USD | -119.2% | +107.2% | — | |
| LTM Mar 2026 | $343K USD | -64.3% | -51.8% | 34.3% | |
| LTM Mar 2026 | $233K USD | -91.2% | -54.6% | — | |
| LTM Mar 2026 | $193.53K USD | -101.5% | — | 0.1% | |
| Peer median (excluding IOVA) | — | -119.2% | -1.4% | 3.5% | |
Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (342.25M) | (395.89M) | (444.04M) | (372.18M) | (390.98M) |
| Depreciation & Amortization | 13.98M | 21.14M | 33.13M | 43.61M | 47.32M |
| Deferred Income Tax | 0 | 0 | (3.48M) | (2.83M) | (2.07M) |
| Stock-Based Compensation | 69.77M | 84.02M | 62.63M | 109.63M | 61.58M |
| Change in Working Capital | 24.55M | (2.89M) | (6.52M) | (122.56M) | (24.27M) |
| Accounts Receivables | 0 | 0 | (149K) | (69.19M) | (13.11M) |
| Inventory | 0 | 0 | (10.12M) | (39.92M) | (14.21M) |
| Accounts Payables | 6.98M | 5.88M | 4.83M | (7.84M) | (6.66M) |
| Other Working Capital | 17.58M | (8.78M) | (1.08M) | (5.61M) | 9.71M |
| Other Non-Cash Items | 6.01M | 871K | (3.54M) | (8.65M) | 6.01M |
| Operating Cash Flow | (227.94M) | (292.76M) | (361.82M) | (352.98M) | (302.41M) |
| Capital Expenditures | (37.57M) | (20.43M) | (22.29M) | (11.07M) | (33.84M) |
| Acquisitions (Net) | (37.71M) | (276.88M) | (212.63M) | (52.57M) | 0 |
| Purchases of Investments | (725.21M) | (245.82M) | (205.9M) | (460.77M) | (318.67M) |
| Sales of Investments | 762.91M | 522.7M | 285.58M | 428M | 400M |
| Other Investing Activities | 37.71M | 276.88M | 0 | 0 | 0 |
| Investing Cash Flow | 132K | 256.46M | (155.24M) | (96.41M) | 47.5M |
| Debt Repayment | 1M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 203.16M | 189.5M | 463.28M | 397.3M | 306.31M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 35.11M | 648K | (322K) | (6.64M) | (7.06M) |
| Financing Cash Flow | 239.27M | 190.15M | 462.96M | 390.66M | 300.77M |
| Effect of Forex Changes | 0 | 0 | (2.74M) | (541K) | 1.52M |
| Net Change in Cash | 11.46M | 153.85M | (56.84M) | (59.27M) | 47.38M |
| Free Cash Flow | (265.52M) | (313.18M) | (384.11M) | (364.05M) | (336.24M) |
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.